Ligand validation:8BDN

QFR: (2~{R})-3-methyl-1-[(2~{S},4~{R})-2-[(5~{R})-5-methyl-5-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-4~{H}-1,2,4-oxadiazol-3-yl]-4-oxidanyl-pyrrolidin-1-yl]-2-(3-methyl-1,2-oxazol-5-yl)butan-1-one

QFR is a Ligand Of Interest in 8BDN designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8BDN_QFR_I_301	62%	60%	0.176	0.97	0.75	0.8	1	-	0	0	100%	1
8BDN_QFR_L_301	55%	60%	0.188	0.956	0.75	0.77	1	-	0	0	100%	1
8BDN_QFR_F_301	54%	58%	0.193	0.96	0.77	0.85	1	-	0	0	100%	1
8BDN_QFR_C_301	50%	60%	0.198	0.95	0.77	0.75	1	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.